Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.32 |
| ▸ | LSS | P48449 | 1/20 | 0.31 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.30 |
| ▸ | DRD1 | P21728 | 2/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.30 |
| ▸ | DRD3 | P35462 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23841452 | 1.00 | NCF1 (0.44) | NCF1CYP2D6CYP1A2CHRM2CHRM1 | |
| SCHEMBL20715643 | 1.00 | NCF1 (0.44) | NCF1CYP2D6CYP1A2CHRM2CHRM1 | |
| SCHEMBL17286011 | 0.88 | HRH3 (0.39) | NCF1CYP2D6CHRM2CHRM1CHRM3 | |
| SCHEMBL7853848 | 0.88 | HRH3 (0.39) | NCF1CYP2D6CHRM2CHRM1CHRM3 | |
| SCHEMBL17285991 | 0.88 | HRH3 (0.39) | NCF1CYP2D6CHRM2CHRM1CHRM3 | |
| SCHEMBL793180 | 0.88 | NCF1 (0.52) | NCF1LSSGNAI3GNAO1GNAI1 | |
| SCHEMBL17830114 | 0.86 | CHRM5 (0.37) | NCF1CYP2D6CHRM2CHRM1CHRM3 | |
| SCHEMBL14820100 | 0.82 | — | — | |
| SCHEMBL23841454 | 0.80 | NCF1 (0.45) | NCF1CYP2D6CYP1A2CHRM2CHRM1 | |
| SCHEMBL16442184 | 0.80 | NCF1 (0.45) | NCF1CYP2D6CYP1A2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2023066204-A1 | SIK INHIBITOR, COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海美悦生物科技发展有限公司 | 2023-04-27 | — | — | WO | disclosed |
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELTION PHARMACEUTICALS LTD (CH) | 2021-12-23 | — | — | US | disclosed |
| US-11136317-B2 | NADPH oxidase 4 inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2021-10-05 | — | — | US | disclosed |
| EP-3310767-B1 | 2,5-DISUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AS NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-07-22 | — | — | EP | disclosed |
| US-20200165235-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-05-28 | — | — | US | disclosed |
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-06-28 | — | — | US | disclosed |
| WO-2017120164-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC (US) | 2017-07-13 | — | — | WO | disclosed |
| US-20170190713-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | WUXI APPTEC (HONG KONG) CO., LIMITED (HK) | 2017-07-06 | — | — | US | disclosed |
| US-9216980-B2 | Methods of use of diazacarbazoles for treating cancer | GENENTECH, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20100063279-A1 | METHOD FOR PRODUCING QUINOLONE CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2130827-A1 | METHOD FOR PRODUCING QUINOLONE CARBOXYLIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-20080300403-A1 | Method for Production of Quinolone-Containing Lyophilized Preparation | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-12-04 | — | — | US | disclosed |
| US-20080300403-A1 | Method for Production of Quinolone-Containing Lyophilized Preparation | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-12-04 | — | — | US | disclosed |
| EP-1930006-A1 | METHOD FOR PRODUCTION OF QUINOLONE-CONTAINING LYOPHILIZED PREPARATION | Daiichi Sankyo Company, Limited (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-7192949-B2 | Substituted bicyclic pyrimidinones as a mitotic kinesin KSP inhibitors | MERCK & CO., INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7176313-B2 | Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | HGF, MET, FLT1 | NCF1 961/4885CYP2D6 447/4885CYP1A2 2171/4885 |
| US-20080300403-A1 | Method for Production of Quinolone-Containing Lyophilized Preparation | NQO2, TREH, CYP51A1 | NCF1 1645/4885CYP2D6 194/4885CYP1A2 610/4885 |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | NCF1 610/4885CYP2D6 4302/4885CYP1A2 3530/4885 |
| US-20200165235-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | NCF1 106/4885CYP2D6 937/4885CYP1A2 137/4885 |
| US-20170190713-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | MKNK2, CYP2J2, PTGS2 | NCF1 3397/4885CYP2D6 562/4885CYP1A2 141/4885 |
| US-11136317-B2 | NADPH oxidase 4 inhibitors | NOX4, NOX1, CYBB | NCF1 106/4885CYP2D6 937/4885CYP1A2 137/4885 |
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | NCF1 106/4885CYP2D6 937/4885CYP1A2 137/4885 |
| US-20100063279-A1 | METHOD FOR PRODUCING QUINOLONE CARBOXYLIC ACID DERIVATIVE | NQO2, QPCT, QARS1 | NCF1 849/4885CYP2D6 102/4885CYP1A2 189/4885 |
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | NCF1 106/4885CYP2D6 937/4885CYP1A2 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.